
Two markers help predict head and neck cancer prognosis
HPV circulating tumor DNA and MRI/PET imaging markers predicted which tumors would respond to chemoradiation as early as two weeks into treatment.
HPV circulating tumor DNA and MRI/PET imaging markers predicted which tumors would respond to chemoradiation as early as two weeks into treatment.
The new test could signal whether treatment is working months earlier than standard imaging scans, allowing doctors to try alternatives sooner, initial results show.
But they should: A cancer found in the throat is now the leading cancer caused by HPV — and 80% of those diagnosed are men.
Vaccines and other policies could help keep in check a disease that’s becoming increasingly common worldwide.
This phase 2 trial also identified a subset of patients with specific mutations who may see the most benefit from the drug.
When the surgical wound doesn’t heal right, it can send some patients back to the operating room.